Clinical Trial Update: Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IPP-204106N on Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports completion of an adaptive dose-finding Phase I/IIa study evaluating IPP-204106N in patients with advanced solid tumors, focus…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• IPP-204106N

Snippet

Sponsor: Elro Pharma | Conditions: All Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED